In the interest of saving time and reducing costs, drug developers are automating the screening process when selecting excipients for solubility.
Evaluating the pharmacological, pharmacokinetical and toxicological properties of a drug candidate during early stages of drug development requires developments of liquid formulations. In order to solubilize compounds that are poorly soluble, solubilizing excipients need to be added. This needs to be done without compromising the concentration of the active pharmaceutical ingredient (API) required to treat a condition at a therapeutic level.1,2
Traditionally, selecting excipients for their solubilization properties has been a manual process, relying on a trial-and-error-based approach to find the most suitable candidate. In the interest of saving time and reducing costs, drug developers are now looking for alternative ways to identify appropriate excipients. What follows is a detailed discussion of how a new high-throughput screening (HTS) method could help reduce the time and eventually the cost taken to find excipients that solubilize and stabilize compounds in liquid form.